Yes Jalaluddin, some are dummy and some are waiting out of sight, is not just a Mexican standoff, is an ambush as well.
Elke, whatever makes more financial sense: some drugs may need a partnership for both research and to finance their development through the FDA's approval, others may not. If there's an offer for cash consideration with a 20/30% premium on the MC, the directors will give their recommendations to the shareholders for approval.
I wouldn't be surprised if next year, especially following the results of Phase II for BTX1503, and with more data coming out of other products trials, BOT 'll either have a series of agreements in place or will be the object of cash bids from big pharmas.
Add to My Watchlist
What is My Watchlist?
